Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Bio-Rad Laboratories, Inc. logo

NYSE · BIO

Bio-Rad Laboratories, Inc.

Healthcare · Medical - Devices

$372.18

Down-$12.22 (-3.18%)

Updated Oct 31, 2026, 6:48 PM

SID Score

5.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
8.47B
P/E ratio
-12.51
Dividend yield
0.00%
52-week range
$236.73 – $396.23
Volume
183.09K
Avg. volume
214.04K

Price performance · BIO

BIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BIO closed at $372.18 after 21 trading sessions, up 0.82% for the selected period.

Last close
$372.18
Period change
+0.82%
Period low
$352.82
Period high
$385.12
Daily close
View OHLC price history
BIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$381.09$384.00$368.445$372.18183.09K
Oct 29, 2026$389.15$390.155$379.235$384.40332.35K
Oct 28, 2026$384.15$388.86$379.79$385.12251.33K
Oct 27, 2026$376.25$381.87$369.33$380.99167.16K
Oct 26, 2026$371.80$376.00$369.755$372.43179.1K
Oct 23, 2026$356.98$371.31$352.46$369.95167.43K
Oct 22, 2026$359.83$367.93$359.83$363.50228.22K
Oct 21, 2026$350.21$362.42$347.29$360.50360.46K
Oct 20, 2026$352.08$356.93$350.49$354.50212.45K
Oct 19, 2026$355.30$356.34$350.61$352.82220.86K
Oct 16, 2026$369.37$369.37$350.77$353.70207.71K
Oct 15, 2026$364.90$368.5399$359.88$364.82247.83K
Oct 14, 2026$367.86$371.07$361.265$362.43297.4K
Oct 13, 2026$369.00$369.43$358.425$363.73132.59K
Oct 12, 2026$369.85$369.85$359.41$364.42181.2K
Oct 9, 2026$364.32$368.6699$361.32$366.16138.98K
Oct 8, 2026$371.99$372.59$353.97$360.40312.02K
Oct 7, 2026$373.16$374.60$363.98$367.92251.9K
Oct 6, 2026$383.38$390.00$367.49$368.83162.54K
Oct 5, 2026$368.07$381.78$363.9601$379.82279.4K
Oct 2, 2026$357.28$369.40$357.28$369.14223.65K

Latest BIO news

The latest Smart Investors Daily articles mentioning BIO.

Stock researchCompany · Overview

BIO research

Overview

Company profile and research snapshot.

Company profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$340.00
Implied upside
—
Analysts
—
BIO recent ratings
DateFirmRatingTarget
Aug 7, 2026RBC CapitalOutperform—
Aug 5, 2026Wells FargoEqual-Weight—
Aug 5, 2026RBC CapitalOutperform—
Aug 5, 2026CitigroupNeutral—
May 15, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading

The microfluidics market presents significant opportunities in laboratory-on-a-chip research, miniaturized diagnostics, pharmaceutical R&D, and personalized medicine. Growth drivers include advancements in IoT integration, point-of-care diagnostics, and high-throughput screening, with North America leading the expansion. Microfluidics Market Microfluidics Market Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Microfluidics Market Report 2026" has been added to ResearchAndMarkets.com's offering. T

Yahoo · Feb 19, 2026

Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By